We’re attending the ESPGHAN congress from 17-20 May in Vienna!
ESPGHAN, The European Society for Paediatric Gastroenterology Hepatology and Nutrition, works to reduce the burden of digestive and nutritional diseases and to improve and promote digestive and nutritional health in paediatric age groups.
This year, we’re excited to bring our own contribution to the 4-day congress with a scientific poster on our latest study on Bifidobacteria, one of the primary colonizers of the newborn intestinal tract. Submitted to the Journal of Pediatric Gastroenterology and Nutrition, the in-vitro study has shown strain Bifidobacterium longum KABP042’s ability to increase Polyphosphate (poly-P) granules, a molecule often associated with a healthier gut barrier.
Don’t miss our poster N169 at the walk-in session on Friday 19 from 14:40 to 15:30
Results have shown that when fed mostly on human milk oligosaccharides (HMOs), the strain KAPB042 synthetizes more Poly-P, which could contribute to a stronger epithelial barrier, increased expression of tight junction proteins Occludin and JAM-1 (essential for maintaining barrier integrity) and of stress-resistance proteins such as HSP27.
This represents an exciting discovery of novel mechanisms that improve the gut barrier and tackle gastrointestinal issues, and we are proud to be contributing to increasing the industry’s understanding of which strains excel at producing beneficial molecules when growing on HMOs.
Meet us on stand #44!
Available on our stand will be informative materials and samples of our partners’ products formulated with our AB-KOLICARE™ blend, which includes the Bifidobacteria longum KAPB042 strain and has shown potential to support the development of a healthy gut microbiota in babies, infants and toddlers. Clinical studies have demonstrated that AB-KOLICARE™ reduces symptoms of functional gastrointestinal disorders such as constipation and is effective in the management of infant colic, reducing duration of symptoms such as crying after just one week.[1],[2]
[1] Asto, E, Huedo, P. (2022). Probiotic Properties of Bifidobacterium longum KABP042 and Pediococcus pentosaceus KABP041 Show Potential to Counteract Functional Gastrointestinal Disorders in an Observational Pilot Trial in Infants. Frontiers In Microbiology. https://doi.org/10.3389/fmicb.2021.741391
[2] Chen, K., Liu, C. (2021). Infantile Colic Treated With Bifidobacterium longum CECT7894 and Pediococcus pentosaceus CECT8330: A Randomized, Double-Blind, Placebo-Controlled Trial. Frontiers In Pediatrics. https://doi.org/10.3389/fped.2021.635176
Our team of experts will welcome visitors and talk through the results of our scientific studies, including insights on the mechanism of action and clinical evidence. You can find out more about the congress here, and learn more about AB-BIOTICS’ range of paediatric health products here. We hope to see you there!
